Targetting esophageal and gastric cancers with monoclonal antibodies

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Targeted therapies, particularly monoclonal antibodies, are emerging as crucial treatments for esophageal, gastric, and gastroesophageal junction cancers.
• Epidermal Growth Factor Receptor (EGFR) overexpression is common in these cancers, and Cetuximab shows radiosensitizing potential.
• Human Epidermal growth factor Receptor 2 (HER2) overexpression is linked to poorer prognosis in gastric cancer, making HER2-targeted therapies like Trastuzumab relevant.

Purpose of the Study:

• To review the role of targeted therapies, including monoclonal antibodies, in the treatment of esophageal, gastric, and gastroesophageal junction cancers.
• To evaluate the efficacy and safety of Cetuximab, Trastuzumab, and Bevacizumab in clinical trials for these malignancies.
• To discuss the ongoing research and future directions for targeted therapy in upper gastrointestinal cancers.

Main Methods:

• Review of clinical trial data, including Phase II and Phase III studies, focusing on monoclonal antibodies targeting EGFR, HER2, and VEGF-A.
• Analysis of studies investigating Cetuximab in combination with radiochemotherapy for esophageal cancer and chemotherapy for gastric/gastroesophageal junction cancer.
• Examination of the Trastuzumab for Gastric Cancer (ToGA) trial and the AVAGAST study evaluating Bevacizumab.

Main Results:

• Phase II trials of Cetuximab with radiochemotherapy for esophageal cancer and with chemotherapy for gastric/gastroesophageal junction cancer have shown encouraging results, pending Phase III confirmation.
• The ToGA trial demonstrated the clinical efficacy and acceptable toxicity of Trastuzumab combined with first-line chemotherapy in HER2-overexpressing gastric/gastroesophageal cancer.
• The AVAGAST study did not meet its primary endpoint of improved overall survival (OS) with Bevacizumab plus chemotherapy in advanced gastric adenocarcinoma.

Conclusions:

• Monoclonal antibodies targeting EGFR and HER2 represent promising therapeutic strategies for esophageal and gastric cancers, with Trastuzumab approved for HER2-positive cases.
• While Cetuximab shows potential, further Phase III trials are needed to confirm its efficacy.
• Bevacizumab targeting angiogenesis did not improve overall survival in advanced gastric cancer in the AVAGAST study, suggesting limitations for this approach in this specific indication.